Skip to main content
. 2012 Oct 8;109(43):17543–17548. doi: 10.1073/pnas.1205867109

Fig. 4.

Fig. 4.

Persistence of Kb/SIINFEKL presentation is attenuated by inhibition of hsp90. (A) Stimulation of B3Z cells by draining lymph node (DLN) cells [day 5 after OVA immunization] treated ex vivo and immediately before the assay, with or without geldanamycin (GA) (25 μM), 17-AAG (50 μM), or SU11652 (1 μM). (B) Stimulation of B3Z cells by purified CD11c positive cells from DLNs (day 7 after OVA immunization) treated ex vivo and immediately before the assay, with or without GA, 17-AAG, or SU11652, as in A. (C) Stimulation of B3Z cells by BMDC-OVA cells (day 5 after OVA pulsing) treated in vitro and immediately before the assay, with or without GA, 17-AAG, or SU11652, as in A. (D) Stimulation of B3Z cells by BMDC-OVA cells, day 5 (black bars) or day 7 (gray bars) after OVA treated, in vitro for 30 min, only on day 0 and immediately after OVA-uptake, with or without GA (25 μM) or 17-AAG (50 μM). In contrast to A and B, no inhibitors were used immediately before the assay. ***P < 0.001. Error bars indicate mean ± SD. A representative of three independent experiments is shown.